Patients who received clopidogrel in the days prior to coronary artery bypass graft (CABG) surgery lost less blood and required fewer blood transfusions when they received Trasylol(R) during their CABG procedure. These findings, published in the September supplement of Circulation - Journal of the American Heart Association, represent an important development for people who benefit from antiplatelet therapy to prevent major adverse cardiac events, including heart attack, stroke and death and who may at some point undergo CABG surgery.(1)
